Pfizer (PFE): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale $1K–$15K
Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale of Pfizer in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 25 days
- Disclosure lag
- Traded
- Mar 13, 2026
- Disclosed
- Apr 7, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jun 17, 2025Congress · 1 personMembers of Congress: 2 purchases
- Dec 19, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
- Dec 31, 2025CongressDisclosed sale of PFE — reported range $100,001 - $250,000
- Jan 23, 2026Federal contract · $22K obligatedDepartment of Defense awarded Pfizer: $22K obligated to date
- Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
- Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
- Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
- Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
- Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
- Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
- Feb 24, 2026FDAFDA drug approval: Braftovi
- Feb 24, 2026FDAFDA drug approval: Braftovi
- Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
- Mar 6, 2026FDAFDA drug approval: Xeljanz
- Mar 6, 2026FDAFDA drug approval: Xeljanz XR
- Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
- Mar 13, 2026 · this disclosureCongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
What came next
- Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
- Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
- Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
- Apr 23, 2026Federal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
- May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 5, 2026Company filing · Form 8-K · ResultsReported its results
- May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
- May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
- May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
- Jun 5, 2026FDAFDA drug approval: Hympavzi
- Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
- Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
- Jun 24, 2026FDAFDA drug approval: Ibrance
- Jun 24, 2026FDAFDA drug approval: Ibrance
- Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Pfizer
For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.
Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)
- House Clerk periodic transaction report at Alexandria Real Estate Equities (ARE)Nov 10, 2026
- House Clerk periodic transaction report at Alliant Energy (LNT)Nov 10, 2026
- House Clerk periodic transaction report at AppLovin (APP)Nov 10, 2026
- House Clerk periodic transaction report at AppLovin (APP)Nov 10, 2026
- House Clerk periodic transaction report at Argenx (ARGX)Nov 10, 2026
The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded Pfizer (PFE) stock, and how much?
Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale of Pfizer in the $1K–$15K range. Reported range, not an exact amount.
When did it happen, and when was it made public?
Traded: Mar 13, 2026. Disclosed: Apr 7, 2026. That is 25 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Pfizer recently?
For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.
Does this mean PFE stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Pfizer
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordNov 12, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its PFE page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
